Rimag Group(02522)

Search documents
智通港股通占比异动统计|9月8日
智通财经网· 2025-09-08 00:41
Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, with notable increases in ownership for certain companies and decreases for others [1][2]. Group 1: Companies with Increased Holdings - Changfei Fiber Optics (06869) saw an increase of 2.14%, bringing its latest holding ratio to 59.98% [2]. - Shandong Gold (01787) experienced a 1.80% increase, with a new holding ratio of 58.88% [2]. - Haotian International Construction Investment (01341) had a 1.51% increase, resulting in a holding ratio of 57.62% [2]. - Over the last five trading days, Shandong Gold (01787) had the highest increase at 6.06%, with a holding ratio of 58.88% [3]. - Changfei Fiber Optics (06869) also increased by 5.95%, reaching a holding ratio of 59.98% [3]. - Yimai Sunshine (02522) saw a 5.52% increase, with a holding ratio of 43.15% [3]. Group 2: Companies with Decreased Holdings - Spring Medical (01858) experienced the largest decrease at -2.53%, with a holding ratio of 44.43% [2]. - BRILLIANCE CHI (01114) saw a reduction of -1.61%, resulting in a holding ratio of 14.02% [2]. - ZTE Corporation (00763) had a decrease of -1.37%, with a holding ratio of 51.54% [2]. - Over the last five trading days, Heng Seng China Enterprises (02828) had the largest decrease at -13.70%, with a holding ratio of 2.71% [3]. - Hong Kong Broadband (01310) decreased by -9.74%, reaching a holding ratio of 0.27% [3]. - The Yingfu Fund (02800) saw a reduction of -4.75%, with a holding ratio of 3.33% [3]. Group 3: Notable Trends - The article provides a detailed list of the top 20 companies with the largest increases and decreases in holdings, indicating significant shifts in investor sentiment [2][3]. - The data reflects a dynamic trading environment, with certain companies gaining traction while others are losing investor interest [1][2].
一脉阳光(02522) - 章程
2025-09-05 13:52
江西一脈陽光集團股份有限公司 章 程 | 第一章 | 總則 | 1 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 2 | | 第三章 | 股份 | 3 | | 第一節 | 股份發行 | 3 | | 第二節 | 股份增減和回購 | 7 | | 第三節 | 股份轉讓 | 8 | | 第四章 | 股東和股東會 | 10 | | 第一節 | 股東 | 10 | | 第二節 | 股東會的一般規定 | 14 | | 第三節 | 股東會的召集 | 17 | | 第四節 | 股東會的提案與通知 | 18 | | 第五節 | 股東會的召開 | 20 | | 第六節 | 股東會的表決和決議 | 23 | | 第五章 | 董事會 | 29 | | 第一節 | 董事 | 29 | | 第二節 | 董事會 | 33 | | 第六章 | 總經理及其他高級管理人員 | 38 | | 第七章 | 監事會 | 40 | | 第一節 | 監事 | 40 | | 第二節 | 監事會 | 41 | | 第八章 | 財務會計制度、利潤分配和審計 | 43 | | 第一節 | 財務會計制度 | 43 | | 第二節 | ...
一脉阳光(02522) - 修订组织章程细则
2025-09-05 13:48
緊隨完成後,本公司註冊資本由人民幣366,061,832元變更為人民幣401,061,832 元,以及已發行股份總數由366,061,832股變更為401,061,832股。為反映本公司 註冊資本及已發行股份總數的相關變動,本公司已對組織章程細則作出相應修訂 (「修訂」)。本公司已於2025年9月5日申請就修訂向贛江新區市場監督管理局辦理 登記及備案程序。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:2522) 修訂組織章程細則 本公告乃根據香港聯合交易所有限公司證券上市規則第13.51(1)條作出。 茲提述江西一脈陽光集團股份有限公司(「本公司」)日期為2025年4月1日有關 (其中包括)發行新股份、出售及 ╱ 或轉讓庫存股份之一般授權的通函(「該通 函」),以及本公司日期為2025年8月22日及20 ...
一脉阳光:中国证监会受理公司H股全流通备案申请
Zhi Tong Cai Jing· 2025-09-04 12:50
Core Viewpoint - The company has submitted a filing application for the full circulation of H-shares concerning 104 million unlisted shares held by several shareholders, representing approximately 25.98% of the total issued share capital as of the announcement date [1] Group 1 - The China Securities Regulatory Commission (CSRC) accepted the company's application on August 25, 2025 [1] - The full circulation of H-shares is pending all relevant approvals, including the CSRC's filing notice and the conversion and listing [1]
一脉阳光(02522):中国证监会受理公司H股全流通备案申请
智通财经网· 2025-09-04 12:44
Core Viewpoint - The company, Yipai Yangguang (02522), has submitted a filing application for the full circulation of H-shares concerning 104 million unlisted shares held by several shareholders, which accounts for approximately 25.98% of the total issued share capital as of the announcement date [1] Group 1 - The China Securities Regulatory Commission (CSRC) accepted the company's application on August 25, 2025 [1] - The full circulation of H-shares is still pending approval from all relevant authorities, including the CSRC's filing notice and the conversion and listing process [1]
一脉阳光(02522.HK):中国证监会受理公司H股全流通备案申请
Ge Long Hui· 2025-09-04 12:43
Core Viewpoint - The company, Yipai Yangguang (02522.HK), has submitted a filing application for the full circulation of H-shares for 104,183,758 unlisted shares held by several shareholders, which accounts for approximately 25.98% of the company's total issued share capital as of the announcement date [1] Group 1 - The China Securities Regulatory Commission (CSRC) updated its website on August 29, 2025, indicating that it accepted the company's application on August 25, 2025 [1] - The full circulation of H-shares is still pending approval from all relevant authorities, including the CSRC's filing notice and the conversion and listing process [1]
一脉阳光(02522) - 内幕消息中国证监会受理本公司H股全流通备案申请
2025-09-04 12:35
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性 或完整性亦不發表任何聲明,並明確表示,概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 內幕消息 中國證監會受理本公司H股全流通備案申請 本公告乃江西一脈陽光集團股份有限公司(「本公司」)根據香港聯合交易所有限公 司證券上市規則(「上市規則」)第13.09(2)(a)條及香港法例第571章證券及期貨條 例第XIVA部項下的內幕消息條文(定義見上市規則)而刊發。 茲提述本公司日期為2025年7月28日的公告(「該公告」),內容有關本公司擬實施 H股全流通。除另有界定外,本公告所用詞彙與該公告所界定者具有相同涵義。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 (於中華人民共和國註冊成立的股份有限公司) (股份代號:2522) H股全流通及轉換及上市須遵守中國證監會、聯交所及其他境內外監管機構要求 的相關程序。本公司股東及有意投資者於買賣本公司證券時務請審慎行事。 承董事會命 江西一脈陽光集團股份有限公司 董事會欣然宣佈,中國證監會網站2025年8月 ...
一脉阳光(02522) - 截至二零二五年八月三十一日止月份之股份发行人的证券变动月报表
2025-09-04 09:57
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 江西一脈陽光集團股份有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 2. 股份分類 | 普通股 | 股份類別 | 其他類別 (請註明) | | 於香港聯交所上市 (註1) | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | | 說明 | 未上市股份 | | | | | | | | 已發行股份(不包括庫存股份)數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 106,933,758 | | 0 | | 106,933,758 | | 增加 / 減少 (-) | | | | | | | | | 本月底結存 | | | 106,933,758 | | 0 | | 106,933,758 | FF301 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) ...
一脉阳光(02522.HK):AI赋能 第三方医学影像龙头发展加速
Ge Long Hui· 2025-09-04 03:57
Industry Insights - The third-party medical imaging service industry in China has significant potential, with a current penetration rate of only 1% compared to over 40% in the US, indicating a vast market opportunity [1] - AI technology is enhancing the medical imaging sector through various applications, including equipment, diagnostic assistance, treatment support, and data quality control, which can lead to cost reduction and efficiency improvements [1] - The third-party imaging centers serve as both producers of imaging data and application scenarios for AI, allowing them to generate additional revenue through licensing AI algorithms and data services [1] Company Overview - The company operates a one-stop ecosystem with three main business segments: imaging center services, imaging solution services, and Yimai Cloud services, which support and transform each other [2] - The imaging center business is the cornerstone of the company's revenue, accounting for over 60% of total income, and serves as a competitive moat due to high market entry barriers [2] - The imaging solution business is poised for growth, with a focus on international expansion, targeting 30% of revenue from overseas markets within five years [2] - The company has launched the world's first full-modal, full-process medical imaging foundation model, with significant collaborations to accelerate AI medical imaging applications [3] - Revenue projections for the company are optimistic, with expected figures of 1.011 billion, 1.286 billion, and 1.588 billion yuan for 2025-2027, reflecting year-on-year growth rates of 32.9%, 27.3%, and 23.5% respectively [3] - The company is positioned as a leader in the domestic third-party medical imaging market, with a unique business model that leverages data and scenario advantages in the AI imaging field [3]
数据交易破冰,政策催化千亿价值释放,一脉阳光凭“基座模型+数据资产”筑护城河
Tai Mei Ti A P P· 2025-09-03 00:35
Core Insights - The implementation of the "AI+" initiative is expected to accelerate both policy benefits and commercial monetization in the AI healthcare sector, with the market size projected to grow from 97.3 billion yuan in 2023 to 159.8 billion yuan by 2028, reflecting a compound annual growth rate of 10.5% [1] - The company Yimai Sunshine (02522) has developed a replicable profit model through "AI foundational model research and data governance," positioning itself as a leader in the AI healthcare space [1][2] Group 1: AI Model Development - The "Yinghe Miyan®" foundational model developed by Yimai Sunshine aligns with the policy directive to enhance foundational capabilities in AI, focusing on theoretical research and model architecture innovation [2] - This model has achieved a generalized capability covering over 200 common diseases and 12 imaging modalities, significantly reducing deployment costs for grassroots hospitals by 40% [2][3] - The upcoming launch of the chest CT AI diagnostic product (AIR) in October 2025 aims to enhance service penetration and revenue potential by enabling multi-disease detection from a single scan [2] Group 2: Clinical Value Transformation - The "Yinghe Miyan®" model facilitates a shift from rigid AI outputs to human-machine collaboration, improving efficiency in complex scenarios and reducing task completion times [3] - This efficiency boost is expected to enhance collaboration with grassroots hospitals, aligning with the policy goal of empowering primary healthcare [3] Group 3: Data Assetization - The policy emphasizes the construction of high-quality datasets and exploring revenue-sharing from data, which addresses industry challenges related to data quality and privacy [4] - Yimai Sunshine has established the largest medical imaging database in China, ensuring high-quality data for AI training through standardized collection and quality control [5] Group 4: Commercialization of Data Assets - Yimai Sunshine has pioneered a compliant data circulation and revenue cycle, successfully listing its "CT chest lesion annotation data" on the Shanghai Data Exchange [6][7] - The company has developed a clear path for monetizing data assets, transforming high-quality imaging data into tradable digital assets, thus diversifying revenue streams beyond traditional medical service fees [7] Group 5: Cross-Industry Integration - The integration of AI and healthcare is driven by mutual reinforcement, with Yimai Sunshine focusing on defining AI development based on clinical needs and involving medical professionals in product design [8][9] - This approach addresses the challenges of AI implementation in clinical settings and enhances the capabilities of grassroots healthcare services, creating a positive feedback loop between technology and medical practice [8][9] Group 6: Strategic Framework - The synergy of data as a resource, foundational models as engines, and clinical integration as a guiding principle forms the core competitive advantage of Yimai Sunshine, offering a sustainable value creation pathway for the industry [9]